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Hereditary Tumors Unit, Istituto Nazionale Tumori, Milan, Italy In Italy, where the health system is mainly public (although the number of private clinics is increasing), genetic counseling on inherited predisposition to cancer and related genetic tests are generally offered on the basis of research projects, lacking specific national guide lines. Genetic counseling services on familial breast and ovarian cancer have been established in Milan, Modena, Naples, Varese and Genoa, while their organization is in progress in Aviano, Chieti, Florence, Padova, Pisa, Rome and Turin. Counseling is usually offered as an outpatient service in the context of medical genetics services departments of oncology, university and/or local programs of mammography screening with direct access for the general population. Due to the different locations and purposes of these services, it is difficult to assess how many Italian women have been evaluated during the last three years. Roughly, we can estimate that approximately 1500 women have been consulted because of a relevant family history of breast/ovarian cancer and/or early onset of the same tumors. Most of the counseling services already established involve multiple health care professionals. Usually, oncologists, medical geneticists, surgeons, gynecologists, psychologists and radiologists collaborate to offer an evaluation of the cancer family history, an estimation of the prior probability of carrying a major genetic defect, breast cancer risk assessment for relatives, psycho-social support and an appropriate follow-up program. Laboratories that already perform molecular screening for germline BRCA1 and BRCA2 are located in Milan, Pisa, Aviano, Modena, Padova, Rome and Turin. Although there are no unified eligibility criteria for BRCA1 and BRCA2 testing, most laboratories and referral counseling services offer a genetic test in the presence of a 10% cut-off prior probability in favor of a genetic defect, with few differences among centers (see Table 1 ). Approximately 730 eligible families have been selected to date, with a free decision in favor of genetic testing ranging from 66% to 86%, depending on personal and familial disease history. For example, refusal of testing was higher among women with early onset ovarian or breast cancer and negative family history (50% and 23%, respectively) than in cases of familial breast cancer (10% refusal). The lowest rate of refusal was observed when the index case had developed multiple tumors (bilateral breast cancer cases: 7%, breast + ovarian cancer cases: 4.5%, all with positive family history). In general, Italian women tend to agree with genetic testing, mainly because they want "to do" something for their family. They believe in the utility of early diagnosis and want to know more about their disease. Many women have experienced in their own case, or in family members, that early diagnosis correlates with a better prognosis and this increases their confidence in the utility of clinical surveillance programs. Among women refusing a genetic test there is a strong worry about the possibility of developing further malignancies (a second breast cancer or an ovarian cancer) and of transmitting the putative genetic defect. As expected, the feeling of danger for daughters is the main reason Short Communication Familial Breast and Ovarian Cancer: Genetic Counseling and Clinical Management in Italy for accepting or refusing a genetic test among Italian women. In Italy, molecular analysis of BRCA genes is performed mainly by PTT (protein truncation test) on BRCA1 exon 11 and BRCA2 exons 10-11 and SSCP (single strand confor-mational polymorphism) on the remaining exons (Aviano, Milan, Padova, Pisa, Rome), direct sequencing (Modena) and Southern blot analysis (Padova, Aviano). To date, among the laboratories contributing data, 166 Italian families carrying deleterious BRCA germline mutations have been identified, 118 in BRCA1 and 48 in BRCA2 genes. In different laboratories, 4-27% of the identified mutations recurred among apparently unrelated families, with slight differences depending on geographic region. In the experience of the National Cancer Institute in Milan, which collected families from all over Italy, just 11.7% of the identified mutations were recurrent in 2 to 13 families. With the exception of BRCA1 5382insC and 1499insA identified in 13 and 4 different families, respectively, the other "recurrent" mutations were usually present in 2 or 3 apparently unrelated families. Therefore, complete screening of both BRCA1 and BRCA2 genes is the testing procedure of choice in Italy. Approximately 280 carriers (211 affected and 69 healthy) have already been identified while 132 at risk family members were non-carriers of specific genetic defects. Although the option of prophylactic breast surgery is generally accepted among the Italian medical community, as far as we know, no Italian woman followed by the referral centers underwent this treatment. Breast prophylactic surgery appears to most Italian women a kind of "over treatment", in relation to the breast cancer risk and from personal family experience. Even on diagnosis of a second breast cancer, the most frequent choice is conservative surgery, although an aesthetic reconstruction is always offered. The general surveillance protocol is based on breast clinical examination every 6 months and annual breast imaging (usually mammography in oblique projection under 35 years of age, and in three projections 
